The U.S. Food and Drug Administration approved TEZSPIRE (tezepelumab-ekko) for treating chronic rhinosinusitis with nasal polyps in adults and pediatric ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE